Chronic pancreatitis

Current Opinion in Gastroenterology

Volumn 20, Issue 5, 2004, Pages 444-451

  DiMagno, Matthew J ^a   DiMagno, Eugene P ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alcohol; Autoimmune; Chronic pancreatitis; Fibrogenesis; Genetics

Indexed keywords

ALCOHOL DEHYDROGENASE; ANTIOXIDANT; BIOLOGICAL MARKER; CANCER GROWTH FACTOR; CHOLECYSTOKININ; CYTOCHROME P450 2E1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INTERLEUKIN 1; INTERLEUKIN 6; LISINOPRIL; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLATELET DERIVED GROWTH FACTOR; SECRETIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; STEROID; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRIACYLGLYCEROL LIPASE; TRYPSINOGEN; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOLIC PANCREATITIS; AUTOIMMUNE DISEASE; CANCER RISK; CELIAC DISEASE; CHRONIC PANCREATITIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DNA MICROARRAY; DRUG EFFECT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPY; ENTERITIS; FIBROGENESIS; GENE MUTATION; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; IRRITABLE COLON; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; METASTASIS; NONHUMAN; ONSET AGE; PANCREAS BIOPSY; PANCREAS CARCINOMA; PANCREAS FUNCTION TEST; PANCREATITIS; PATHOGENESIS; PHENOTYPE; PLASMACYTOMA; PRIMARY SCLEROSING CHOLANGITIS; PROTEOMICS; REVIEW; SHORT BOWEL SYNDROME; SJOEGREN SYNDROME; STELLATE CELL; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

EID: 4344563356     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200409000-00005     Document Type: Review

References (94)

1. DiMagno MJ, DiMagno EP: Chronic pancreatitis. Curr Opin Gastroenterol 2003, 19:451-457.
2. Beharry S, Ellis L, Corey M, et al.: How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr 2002, 141:84-90.
3. Schappi MG, Smith VV, Cubitt D, et al.: Faecal elastase 1 concentration is a marker of duodenal enteropathy. Arch Dis Child 2002, 86:50-53.
4. Nousia-Arvanitakis S: Fecal elastase-1 concentration: an indirect test of exocrine pancreatic function and a marker of an enteropathy regardless of cause. J Pediatr Gastroenterol Nutr 2003, 36:314-315.
5. Carroccio A, Verghi F, Santini B, et al.: Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Italian Society of Pediatric Gastroenterology and Hepatology. Dig Dis Sci 2001, 46:1335-1342.
6. Salvatore S, Finazzi S, Barassi A, et al.: Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. J Pediatr Gastroenterol Nutr 2003, 36:392-396.
7. Conwell DL, Zuccaro G, Morrow JB, et al.: Analysis of duodenal drainage fluid after cholecystokinin (CCK) stimulation in healthy volunteers. Pancreas 2002, 25:350-354.
8. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al.: Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002, 21:4587-4594.
9. Crook MA: Long-chain polyunsaturated fatty acids and diabetes mellitus. Nutrition 2003, 19:166-167.
10. Czako L, Takacs T, Hegyi P, et al.: Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis. Can J Gastroenterol 2003, 17:597-603.
11. Afzalpurkar RG, Schiller LR, Little KH, et al.: The self-limited nature of chronic idiopathic diarrhea. N Engl J Med 1992, 327:1849-1852.
12. Somogyi L, Ross SO, Cintron M, et al.: Comparison of biologic porcine secretin, synthetic porcine secretin, and synthetic human secretin in pancreatic function testing. Pancreas 2003, 27:230-234. The three forms of secretin are equivalent and can be used interchangeably for pancreatic function testing.
13. Raimondo M, Imoto M, DiMagno EP: Rapid endoscopic secretin stimulation test and discrimination of chronic pancreatitis and pancreatic cancer from disease controls. Clin Gastroenterol Hepatol 2003, 1:397-403. In a large study of 412 persons, bicarbonate concentrations were not accurate. Although lipase concentrations were significantly lower in patients with chronic pancreatitis and pancreatic cancer compared with people with a normal pancreas, they were not accurate enough for routine clinical use (PPV, 73%; negative predictive value, 85%).
14. Conwell DL, Zuccaro G Jr, Vargo JJ, et al.: An endoscopic pancreatic function test with cholecystokinin-octapeptide for the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol 2003, 1:189-194. See[15•].
15. Conwell DL, Zuccaro G Jr, Vargo JJ, et al.: An endoscopic pancreatic function test with synthetic porcine secretin for the evaluation of chronic abdominal pain and suspected chronic pancreatitis. Gastrointest Endosc 2003, 57:37-40. In [15•], patients were given cholecystokinin octapeptide, and in [14•], patients were given secretin. In both studies, duodenal juice was collected through an endoscope in the duodenum for as long as 80 minutes. They report high sensitivity, but there is significant overlap of values among groups, and the long collection times detract from a major attraction of a short test.
16. Draganov P, George S, Toskes PP, et al.: Is a 15-minute collection of duodenal secretions after secretin stimulation sufficient to diagnose chronic pancreatitis? Pancreas 2004, 28:89-92.
17. Friess H, Ding J, Kleeff J, et al.: Identification of disease-specific genes in chronic pancreatitis using DNA array technology. Ann Surg 2001, 234:769-778; discussion 778-769.
18. Logsdon CD, Simeone DM, Binkley C, et al.: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003, 63:2649-2657.
19. Logsdon CD: Commentary on: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. February 27, 2004. Available at: http://www.PancreasWeb.com.
20. Hu L, Evers S, Lu ZH, et al.: Two-dimensional protein database of human pancreas. Electrophoresis 2004, 25:512-518. Application of this technique to samples of blood and pancretic secretions may enhance diagnosis of chronic pancreatitis. Complete list of human pancreatic proteins identified by this technique is available at http://www.wiley-vch.de/contents/jc_2027/2004/ el5683_s.pdf.
21. Layer P, Yamamoto H, Kalthoff L, et al.: The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994, 107:1481-1487.
22. Jaskiewicz K, Nalecz A, Rzepko R, et al.: Immunocytes and activated stellate cells in pancreatic fibrogenesis. Pancreas 2003, 26:239-242.
23. +) in all three groups. Unfortunately, differences among the groups may have been missed, because the patients with alcoholic chronic pancreatitis likely had an inflammatory mass in the head of the pancreas, and the patients with ICP were not segregated to early-onset and late-onset groups. Further, the authors failed to explain how clearly discernible pathologic differences in some chronic pancreatitis groups (eg, endophlebitis in TCP) and clear differences in natural histories of etiologically distinct forms of chronic pancreatitis support their hypothesis that a common immunologic change underlies all causes of chronic pancreatitis.
24. Friess H, Shrikhande S, Shrikhande M, et al.: Neural alterations in surgical stage chronic pancreatitis are independent of the underlying aetiology. Gut 2002, 50:682-686.
25. Keim V, Witt H, Bauer N, et al.: The course of genetically determined chronic pancreatitis. JOP 2003, 4:146-154.
26. Howes N, Lerch MM, Greenhalf W, et al.: Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004, 2:252-261. By applying strict criteria, the investigators found, compared with previous publications, a higher frequency of mutations of R122H, N29I, or A16V, greater disease penetrance, and a higher lifetime pancreatic cancer risk, and found that the onset of pancreatic cancer occurred 14 years earlier in smokers. In addition, in contrast with previous studies, the common R122H mutation was not associated with more aggressive disease, but these people sought treatment 4 to 5 years earlier than people with N29I or no identifiable mutations and were more frequently hospitalized than the N29I patients. Patients with N29I mutations, however, were treated at an earlier age with pancreatic resection for pain.
27. Kloppel G, Luttges J, Lohr M, et al.: Autoimmune pancreatitis: pathological, clinical, and immunological features. Pancreas 2003, 27:14-19. An important review that summarizes current knowledge of the pathologic, clinical, and immunologic features of autoimmune pancreatitis.
28. DiMagno EP: Autoimmune chronic pancreatitis: a plea for simplification and consistency. Clin Gastroenterol Hepatol 2003, 1:421-422.
29. Notohara K, Burgart LJ, Yadav D, et al.: Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol 2003, 27:1119-1127.
30. Yadav D, Notahara K, Smyrk TC, et al.: Idiopathic tumefactive chronic pancreatitis: clinical profile, histology, and natural history after resection. Clin Gastroenterol Hepatol 2003, 1:129-135. Description of idiopathic tumefactive pancreatitis: LPSP characterized by periductal lymphoplasmacytic infiltration, obliterative phlebitis and cholangitis with edema, and IDCP characterized by neutrophil-predominant tabular inflammation without phlebitis. This terminology confounds rather than clarifies the classification of chronic pancreatitis. See [28] for further comment.
31. Steinberg WM, Barkin JS, Bradley EL 3rd, et al.: Controversies in clinical pancreatology: autoimmune pancreatitis: does it exist? Pancreas 2003, 27:1-13.
32. Okazaki K, Chiba T: Autoimmune related pancreatitis. Gut 2002, 51:1-4.
33. Hirano K, Shiratori Y, Komatsu Y, et al.: Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol 2003, 1:453-464. Intrahepatic or extrahepatic bile duct abnormalities may be present at diagnosis or develop during the course of autoimmune pancreatitis. They respond to steroids (as do the pancreatic abnormalities), whereas the abnormalities of PSC do not.
34. Whitcomb DC, Gorry MC, Preston RA, et al.: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996, 14:141-145.
35. Applebaum-Shapiro SE, Finch R, Pfutzer RH, et al.: Hereditary pancreatitis in North America: the Pittsburgh-Midwest Multi-Center Pancreatic Study Group Study. Pancreatol 2001, 1:439-443.
36. Witt H, Luck W, Hennies HC, et al.: Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000, 25:213-216.
37. Noone PG, Zhou Z, Silverman LM, et al.: Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology 2001, 121:1310-1319.
38. Cohn JA, Friedman KJ, Noone PG, et al.: Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998, 339:653-658.
39. Sharer N, Schwarz M, Malone G, et al.: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998, 339:645-652.
40. Bernardino AL, Guarita DR, Mott CB, et al.: CFTR, PRSS1 and SPINK1 mutations in the development of pancreatitis in Brazilian patients. JOP 2003, 4:169-177.
41. Rossi L, Pfutzer RH, Parvin S, et al.: SPINK1/PSTI mutations are associated with tropical pancreatitis in Bangladesh: a preliminary report. Pancreatology 2001, 1:242-245.
42. Bishop MD, Freedman SD, Zielenski J, et al.: Does complete DNA analysis identify a higher percentage of cystic fibrosis gene mutations in patients with idiopathic chronic and recurrent acute pancreatitis? Gastroenterology 1999, 116:A1113:G4825.
43. Choudari CP, Yu AC, Imperiale TF, et al.: Significance of heterozygous cystic fibrosis gene (cystic fibrosis transmembrane conductance regulator mutations) in idiopathic pancreatitis. Gastroenterology 1998, 114:A447.
44. Steinberg WM, Chari ST, Forsmark CE, et al.: Controversies in clinical pancreatology: management of acute idiopathic recurrent pancreatitis. Pancreas 2003, 27:103-117.
45. Pezzilli R, Morselli-Labate AM, Mantovani V, et al.: Mutations of the CFTR gene in pancreatic disease. Pancreas 2003, 27:332-336.
46. Hanck C, Schneider A, Whitcomb DC: Genetic polymorphisms in alcoholic pancreatitis. Best Pract Res Clin Gastroenterol 2003, 17:613-623.
47. Otsuki M, Nishimori I, Hayakawa T, et al.: Hereditary pancreatitis: clinical characteristics and diagnostic criteria in Japan. Pancreas 2004, 28:200-206.
48. Simon P, Weiss FU, Zimmer KP, et al.: Spontaneous and sporadic trypsinogen mutations in idiopathic pancreatitis. JAMA 2002, 288:2122.
49. Lowenfels AB, Maisonneuve P, Whitcomb DC, et al.: Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001, 286:169-170.
50. Gorry MC, Gabbaizedeh D, Furey W, et al.: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology 1997, 113:1063-1068.
51. Chen JM, Mercier B, Audrezet MP, et al.: Mutational analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and sporadic chronic pancreatitis. J Med Genet 2000, 37:67-69.
52. Pfutzer RH, Barmada MM, Brunskill AP, et al: SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000, 119:615-623.
53. Steer ML, Meldolesi J: The cell biology of experimental pancreatitis. N Engl J Med 1987, 316:144-150.
54. Teich N, Le Marechal C, Kukor Z, et al.: Interaction between trypsinogen isoforms in genetically determined pancreatitis: mutation E79K in cationic trypsin (PRSS1) causes increased transactivation of anionic trypsinogen (PRSS2). Hum Mutat 2004, 23:22-31.
55. Szmola R, Kukor Z, Sahin-Toth M: Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors. J Biol Chem 2003, 278:48580-48589.
56. Chen JM, Le Marechal C, Lucas D, et al.: "Loss of function" mutations in the cationic trypsinogen gene (PRSS1) may act as a protective factor against pancreatitis. Mol Genet Metab 2003, 79:67-70.
57. Halangk W, Kruger B, Ruthenburger M, et al.: Trypsin activity is not involved in premature, intrapancreatic trypsinogen activation. Am J Physiol Gastrointest Liver Physiol 2002, 282:G367-G374.
58. Imamura T, Asada M, Vogt SK, et al.: Protection from pancreatitis by the zymogen granule membrane protein integral membrane-associated protein-1. J Biol Chem 2002, 277:50725-50733.
59. Whitcomb DC: How to think about SPINK and pancreatitis. Am J Gastroenterol 2002, 97:1085-1088.
60. Bhatia E, Choudhuri G, Sikora SS, et al.: Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology 2002, 123:1020-1025.
61. Le Marechal C, Chen JM, Le Gall C, et al.: Two novel severe mutations in the pancreatic secretory trypsin inhibitor gene (SPINK1) cause familial and/or hereditary pancreatitis. Hum Mutat 2004, 23:205.
62. Kuwata K, Hirota M, Nishimori I, et al.: Mutational analysis of the pancreatic secretory trypsin inhibitor gene in familial and juvenile pancreatitis in Japan. J Gastroenterol 2003, 38:365-370.
63. Felderbauer P, Hoffmann P, Einwachter H, et al.: A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. BMC Gastroenterol 2003, 3:34.
64. Freedman SD, Blanco PG, Zaman MM, et al.: Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004, 350:560-569. Patients with cystic fibrosis had an increased arachidonic acid to docosahexanoic acid ratio in phospholipids from nasal and rectal mucosal scrapings. The authors proposed that the membrane changes mighi contribute to the multiorgan inflammatory changes present in cystic fibrosis. Restoring normal tissue arachidonic acid:docosahexanoic acid ratios associated with CFTR mutations holds therapeutic promise [65], but this needs to be verified in large, prospective, controlled studies [74].
65. Freedman SD, Katz MH, Parker EM, et al.: A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci U S A 1999, 96:13995-14000.
66. Xu Y, Clark JC, Aronow BJ, et al.: Transcriptional adaptation to cystic fibrosis transmembrane conductance regulator deficiency. J Biol Chem 2003, 278:7674-7682.
67. Norkina O, Kaur S, Ziemer D, et al.: Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004, 286:G1032-1041.
68. DiMagno MJ, Lee SH, Hao Y, et al.: Susceptibility to acute pancreatitis in classic & nonclassic cystic fibrosis (CF) may be due to increased pancreatic inflammatory mediators: evidence in UNC CFTR (-/-) mice. Pancreas 2003, 27:A377.
69. Muhlebach MS, Stewart PW, Leigh MW, et al.: Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999, 160:186-191.
70. Raia V, Maiuri L, de Ritis G, et al.: Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 2000, 47:344-350.
71. DiMagno MJ: Commentary on: Association of cystic fibrosis with abnormalities in fatty acid metabolism. April 1, 2004. Available at: http://www.PancreasWeb.com.
72. Nakamura MT, Nara TY: Essential fatty acid synthesis and its regulation in mammals. Prostaglandins Leukot Essent Fatty Acids 2003, 68:145-150.
73. Quilliot D, Walters E, Bohme P, et al.: Fatty acid abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus. Eur J Clin Nutr 2003, 57:496-503.
74. Beckles Willson N, Elliott TM, Everard ML: Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst Rev 2002:CD002201. See [64••].
75. Corrao G, Bahnardi V, Zambon A, et al.: A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004, in press.
76. Dufour MC, Adamson MD: The epidemiology of alcohol-induced pancreatitis. Pancreas 2003, 27:286-290.
77. Ockenga J, Vogel A, Teich N, et al.: UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. Gastroenterology 2003, 124:1802-1808.
78. Verlaan M, Te Morsche RH, Roelofs HM, et al.: Genetic polymorphisms in alcohol-metabolizing enzymes and chronic pancreatitis. Alcohol Alcohol 2004, 39:20-24.
79. Schneider A, Pfutzer RH, Barmada MM, et al.: Limited contribution of the SPINK1 N34S mutation to the risk and severity of alcoholic chronic pancreatitis: a report from the United States. Dig Dis Sci 2003, 48:1110-1115.
80. Chandak GR, Idris MM, Reddy DN, et al.: Absence of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in hereditary and non-hereditary chronic pancreatitis. Gut 2004, 53:723-728.
81. Jerrells TR, Chapman N, Clemens DL: Animal model of alcoholic pancreatitis: role of viral infections. Pancreas 2003, 27:301-304. Infection may be an important cofactor in alcoholic pancreatitis; alcohol fed mice coinfected with virulent or nonvirulent CVB3 developed severe acute pancreatitis, whereas alcohol or CVB3 alone caused no injury.
82. Verlaan M, te Morsche RH, Roelofs HM, et al.: Glutathione S-transferase Mu null genotype affords protection against alcohol induced chronic pancreatitis. Am J Med Genet 2003, 120A:34-39.
83. Schneider A, Whitcomb DC: Hereditary pancreatitis: a model for inflammatory diseases of the pancreas. Best Pract Res Clin Gastroenterol 2002, 16:347-363.
84. Apte MV, Wilson JS: Alcohol-induced pancreatic injury. Best Pract Res Clin Gastroenterol 2003, 17:593-612.
85. Brenner DA, Rippe RA: Pathogenesis of hepatic fibrosis. In Textbook of Gastroenterology, edn 4. Edited by Yamada T, Alpers DH, Kaplowitz N, et al. Lippincott Williams and Wilkins; 2003.
86. Phillips PA, McCarroll JA, Park S, et al.: Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut 2003, 52:275-282.
87. Zimmermann A, Gloor B, Kappeler A, et al.: Pancreatic stellate cells contribute to regeneration early after acute necrotising pancreatitis in humans. Gut 2002, 51:574-578.
88. Apte MV, Wilson JS: Stellate cell activation in alcoholic pancreatitis. Pancreas 2003, 27:316-320.
89. Lugea A, Gukovsky I, Gukovskaya AS, et al.: Nonoxidative ethanol metabolites alter extracellular matrix protein content in rat pancreas. Gastroenterology 2003, 125:1845-1859.
90. Masamune A, Satoh M, Kikuta K, et al.: Inhibition of p38 mitogen-activated protein kinase blocks activation of rat pancreatic stellate cells. J Pharmacol Exp Ther 2003, 304:8-14.
91. McCarroll JA, Phillips PA, Park S, et al.: Pancreatic stellate cell activation by ethanol and acetaldehyde: is it mediated by the mitogen-activated protein kinase signaling pathway? Pancreas 2003, 27:150-160.
92. Kuno A, Yamada T, Masuda K, et al.: Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003, 124:1010-1019. In vivo, investigators ameliorated inflammatory and fibrotic parameters of chronic pancreatitis using antifibrotic treatments in rats, presumably by inhibiting the profibrotic TGF-β pathway using the angiotensin-converting enzyme inhibitor, Lisinopril.
93. Kuno A, Yamada T, Masuda K, et al.: Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003, 124:1010-1019.
94. Atten JJ, Verma A, Liu K, et al.: Antioxidants up-regulate PPARγ and decrease fibrosis in chronic pancreatitis. Am J Gastroenterol 2003, 98:S64.